Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 44.11M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 89.81M | Net Debt 2020 | 874K 70.05M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | 3 |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Lois Chandler
COO | Chief Operating Officer | - | 30/06/10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 21/12/03 | |
James Grainer
CHM | Chairman | 69 | 21/05/20 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 21/05/20 |
1st Jan change | Capi. | |
---|---|---|
-.--% | 64 | |
+0.17% | 42.86B | |
+10.92% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.23% | 25.15B | |
-24.79% | 18.63B | |
+26.69% | 12.37B | |
-3.13% | 11.92B | |
+6.57% | 11.21B |
- Stock Market
- Equities
- CRXM Stock